Charts

The Pfizer of tomorrow will be larger and even more lucrative to hold than it is now.

UBS (NYSE:UBS) has offered to buy Credit Suisse (NYSE:CS) for up to $1B in an all-share deal, with the Swiss government planning to change laws to bypass a shareholder vote on the deal, according to a Financial Times report today. The proposed deal is set to be signed as soon as Sunday evening at a fraction of Credit Suisse's closing price on Friday. This week alone, Credit Suisse's shares have dropped more than 24% amid a series of scandals that have led to a decline in investor and client confidence, forcing the company to obtain $54B in central bank funding.

Superstar recording artist Nick Jonas shares his experience with diabetes and why he's using his platform to improve access to diabetes care. Nick joins Yahoo Finance Senior Reporter Allie Garfinkle from SXSW in Austin, TX to discuss how health technology like continuous glucose monitoring (CGM) is easing the burden of managing diabetes.  Watch as Nick opens up about his partnership with DexCom (DXCM), fatherhood, and his struggle with diabetes. 

Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had entered an unusual global deal with Seagen.

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

FDA's Antimicrobial Drugs Advisory Committee (AMDAC) votes 16 to 1 for Pfizer's Paxlovid for the treatment of mild-to-moderate COVID-19 in adult patients at high risk of hospitalization or death.

The World Health Organization said Friday that it expects to declare an end to the COVID-19 pandemic sometime in 2023.

Pfizer Inc(NYSE: PFE) andAstellas Pharma Inc(OTC: ALPMY)released topline resultsfrom the Phase 3 EMBARK ...

Pfizer (PFE) is set to buy Seagen (SGEN) for $43 billion while Sanofi (SNY) is acquiring Provention Bio. Novo Nordisk (NVO) and Sanofi are looking to cut insulin prices.

Benzinga The Inevitable End - SVB Financial Officially Files For Bankruptcy In New York SVB Financial Group(NYSE: SIVB) ...

The FDA's Antimicrobial Drugs Advisory Committeevoted 16-1that available data support the safety and effectiveness ...

An approved RSV vaccine could be the next big thing for these companies.

Pfizer Inc(NYSE: PFE)recalledprescription migraine drugs Nurtec ODT 75 mg orally disintegrating tablets sold in ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These are the high-yield dividend stocks to buy for 100% total returns in 2023 in anticipation of a rally from deeply oversold levels. The post 7 High-Yield Dividend Stocks That Can Double Your Money in 2023 appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although investors are freaking out over the banking sector fallout, bold contrarians may consider these stocks to buy. The post 7 Stocks Set to Soar When the Market Recovers appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI® (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence (BCR). Patients enrolled in the trial were randomized to one of three study arms: XTANDI plus l

Pfizer’s COVID-19 pill Paxlovid won another vote of confidence from U.S. health advisers Thursday, clearing the way for its full regulatory approval by the Food and Drug Administration. The medication has been used by millions of Americans since the FDA granted it emergency use authorization in late 2021. The agency has the final say on giving Pfizer's drug full approval and is expected to decide by May.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data support the safety and effectiveness of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe illness. The AMDAC's vote, while not binding, will be considered by the FDA when making its decision regarding the potential approval of PAXLOVID.

A Food and Drug Administration advisory committee voted 16-1 that the benefits of Pfizer’s (PFE) COVID antiviral Paxlovid outweigh the risks in adults who are at high risk of severe disease. The FDA is not required to follow the advice of the committee but often does. It can be prescribed to teens and adults who are at high risk of progressing to severe disease.

Stifelhas initiated coverage onTheseus Pharmaceuticals Inc(NASDAQ: THRX) with a Buy rating anda $24 price ...

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this ...

Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.

It might not regularly beat the market, but it won't have any trouble padding your wallet.

Pfizer Inc said on Thursday it was working on a new child-proof packaging for its migraine drug, Nurtec ODT, after safety concerns led to a recall alert from the U.S. Consumer Product Safety Commission (CPSC). Consumers should immediately secure the recalled product out of the sight and reach of children and contact Pfizer for a free child-resistant pouch to store it, the CPSC said.

Is Pfizer stock a buy or a sell after the company announced its $43 billion plan to buy Seagen? Is PFE stock a buy or a sell?

Advisers to the U.S. Food and Drug Administration on Thursday overwhelmingly backed full approval of Pfizer's oral antiviral COVID-19 treatment Paxlovid for adults at high risk of progression to severe disease. The FDA's panel of outside experts voted 16-to-1 in favor of the drug's benefits outweighing its risk for some adults with mild-to-moderate COVID-19. The agency is expected to make a formal approval decision by May and typically follows the advice of its expert advisers, but is not required to do so.

Many investors appear to be writing off Pfizer. That could prove to be a mistake.

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Pfizer Inc (PFE) has taken over the #27 spot from Oracle Corp (ORCL), according to The Online Investor. Click here to find out the top S&P 500 components ordered by average analyst rating » Market capitalization is an important data point for investors to keep an eye on, for various reasons..

Symbols mentioned in this story: IWD, PFE, WFC, DIS Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) ...

The FDA hasexpandedthe emergency use authorization (EUA) ofPfizer Inc(NYSE: PFE) /BioNTech ...

Three years into the pandemic, the World Health Organization's Joachim Hombach talks about the future of vaccines with MarketWatch.

In the past year, PFE's share price fell $10.39, or about 20.7%.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The vaccine stocks Pfizer, Moderna, and Novavax all have approved Covid-19 vaccines. They'll soon need new sources of revenue. The post 3 Vaccine Stocks to Watch for Their Post-Pandemic Moves appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These dividend stocks are trading at attractive valuations, offering incredible stability in the current trading environment The post 7 Undervalued Dividend Stocks for Your Must-Buy List appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

TheFDAdropped in briefing document as the agency's external advisors meet on Thursday (March 16) to discuss complete ...

Pfizer's planned acquisition of Seagen could be a very important move.

(Tuesday Market Open)The first of this week’s three critical data releases, February’sConsumer Price ...

Pfizer's $43 billion Seagen acquisition is a long-term value-creation strategy.

Pfizer Inc (NYSE: PFE) agreed to acquire Seagen Inc (NASDAQ: SGEN) for $229 in cash per Seagen share for a total enterprise value of $43 ...

Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines andhighly critical of Dr. Anthony Fauci, who in his previous ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Seagen Inc. (NasdaqGS: SGEN) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Seagen will receive $229 in cash for each share of Seagen that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

On a volatile market day, companies are still looking for smart combinations.

Pfizer plans to pay $229 per share in cash for Seagen, whose stock soared more than 15% in trading on Monday afternoon. Pfizer’s shares gained about 1.7%.

Bristol Myers Squibb & Co's(NYSE: BMY) Eliquis,Pfizer Inc's(NYSE: PFE) Ibrance, andAbbVie ...

Investors are cheering Pfizer's planned acquisition of Seagen.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Seagen (SGEN) stock is taking off on Monday as investors react to a $43 billion acquisition agreement with Pfizer (PFE). The post SGEN Stock Alert: Pfizer Buys Seagen in GIANT $43 Billion Deal appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Dow Jones whipsawed after its steep plunge on Friday as bank run fears led investors to safe havens.

Here are some of the biggest movers on Monday with banks in focus after federal regulators stepped into protect deposits at fallen bank SVB.

Pfizer will buy Seagen for roughly $43 billion, and Sanofi will buy Provention for $2.9 billion. SGEN stock and PRVB stock soared.

Pfizer Inc(NYSE: PFE) hasagreed to acquireSeagen Inc(NASDAQ: SGEN) for $229 in cash per Seagen share for a ...

Seagen Inc (NASDAQ: SGEN) shares are trading higher Monday afterPfizerInc (NYSE: PFE)announced plans toacquire ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR Portfolio S&P 500 Growth ETF (SPYG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $61.65 per unit.

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These undervalued stocks to buy are trading at hefty bargains offering tremendous upside potential ahead in the not-so-distant future The post The 7 Most Undervalued Stocks to Buy in March 2023 appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Even if you start out a bit late, it’s never too late, as these compelling investment opportunities for beginning investors prove. The post 7 Compelling Investment Opportunities for Beginning Investors in Their 30s appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Going with these great dividend stocks is an easy choice.

The stock has brought investors eye-popping gains and losses over the past few years.

TheFDA has approvedPfizer Inc(NYSE: PFE) acquired Biohaven's Zavzpret (zavegepant), the first and only ...

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults. In its pivotal Phase 3 study, ZAVZPRET was statistically superior to placebo on the co-primary endpoints of pain freedom and freedom from most bothersome symptom at two hours post-dose. The pivotal study also demonstrated pain relief as early as 15 minutes in a prespecified secondary endpoint versus placebo.

Investors in Pfizer Inc (PFE) saw new options become available today, for the April 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options chain for the new April 28th contracts and identified one put and one call contract of particular interest.